中文版
 
R&D PORTFOLIO
/ SNP-810 (SAFETYNADOL)

steam堡垒之夜英文名:SNP-810 (SAFETYNADOL)

堡垒之夜标志 www.stggs.icu

Indication
Hepatotoxicity-free Acetaminophen (Analgesic and antipyretic)
Product Advantages
1. Hepatotoxicity-free
2. To address the important and urgent unmet medical needs
3. A patented formulation with great safety margin
Status
Phase I low-dose, high-dose completed (Pivotal trial applying for USFDA NDA)
Competitive Edge
1. Currently, no hepatotoxicity-free acetaminophen on the market
2. Great impact on the market share of pain controllers, especially to NSAIDS, Cox2 inhibitors and opioids
3. Reduction of lawsuit and compensation
Potential Market
Acetaminophen sales are 1.3 billion USD a year (US only)

Mechanism of Action of SNP-810 and NAC